Key Highlights:

  • Enlivex shares fell 11.70% to $0.1759 on Friday, October 23, 2026.
  • The company announced a workforce reduction of about 60% on October 19, 2026.
  • A 1-for-16 reverse split will cut ordinary shares from 24,511,905 to about 1,531,995.
  • Management salaries are being cut 20%, and the chief executive's salary is being cut 40%.
  • Topline six-month Phase 2b data for Allocetra in knee osteoarthritis are expected by mid-2027.

Enlivex Stock: What Should Investors Know About the 12% Drop?

Enlivex (NASDAQ:ENLV) shares fell 11.70% to $0.1759 on Friday, October 23, 2026, from a prior close of about $0.20 (calculated). The move followed two company announcements within four days: a cost reduction plan on October 19 and a 1-for-16 reverse stock split announced on October 22.

The cost plan cuts the workforce by about 60%, winds down research and development that is not tied to the Phase 2b trial, and reduces management pay. The company said the plan is meant to substantially reduce cash burn and focus resources on the trial.

The company also warned that it may be unable to obtain financing on acceptable terms to fund the study through topline data.

Reverse Split Details: How Will 1-for-16 Change the Share Count?

Every 16 ordinary shares will be combined into one, with trading on the Nasdaq Capital Market continuing under the ticker ENLV on a split-adjusted basis. The company announced the effective date as October 27, 2026; one report referred to the following Monday, so the exact first trading day should be confirmed with the company.

Ordinary shares outstanding will fall from 24,511,905 to about 1,531,995, subject to rounding of fractions. Authorized shares will fall from 158,333,333 to 9,895,833, and options and warrants will be adjusted in proportion.

At the current price, the split-adjusted equivalent would be about $2.81 per share (calculated), and the equity value would stay near $4.3 million (calculated). The company did not state a Nasdaq bid price deficiency as the reason for the split.

Phase 2b Trial: What Is Enlivex Still Funding?

Enlivex is an Israel-based clinical-stage company developing Allocetra, a therapy for knee osteoarthritis. The Phase 2b study is global, randomized, double-blind and placebo-controlled, using intra-articular injections in patients aged 64 and older with moderate-to-severe knee osteoarthritis.

Six-month topline data are expected by mid-2027. In September 2025 the company said its Phase 2a study showed a 72% pain reduction versus placebo at three months in patients aged 60 and over with primary knee osteoarthritis, and that no drug-related serious adverse events were reported.

Financial Context: How Much Cash Does Enlivex Have?

The October 19 filing gave no dollar figure for savings, cash balance, cash burn or restructuring charges, though it said restructuring charges are possible. The company has not announced a cash runway.

With a market value near $4.3 million (calculated), the company is small relative to the cost of a global Phase 2b trial, which explains why management has narrowed spending to that single program.

The company has said it is pursuing a partnership and non-dilutive funding, but has not announced a deal.

What to Watch Next: Can Enlivex Fund the Phase 2b Trial Through Mid-2027?

The takeaway is that the company has reduced its operating base to protect one trial, while the reverse split changes the share count but not the equity value. The next dated catalyst is the split taking effect on October 27, 2026, followed by Phase 2b topline data expected by mid-2027. Any financing or partnership announcement would be the other item to follow.

The shares fell 11.70% to $0.1759 after the company announced a workforce cut of about 60% and a 1-for-16 reverse split.

The company announced an effective date of October 27, 2026, reducing shares outstanding to about 1,531,995.

Six-month topline data for Allocetra in knee osteoarthritis are expected by mid-2027.